Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Trailing Twelve Months EPS: $5.65
2024 EPS Estimate: ($1.20)
2025 EPS Estimate: ($1.44)
- Current Stock Price
- $12.70
- P/E Ratio
- 2.2
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $17.93 (41.2% Upside)
